Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label pilot study of sirolimus for PIK3CA-related segmental overgrowth
2014-005320-10Phase 2Completed
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sirolimus in PIK3CA-related overgrowth spectrum (PROS) and Segmental overgrowth, sponsored by Centre Hospitalier Universitaire Dijon Bourgogne. Started Jun 2015; status: completed.
02
Drugs
sirolimus
03
Conditions
PIK3CA-related overgrowth spectrum (PROS)Segmental overgrowth
Beyond the preview
Go deeper on 2014-005320-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005320-10.